Medical therapy for inflammatory bowel disease

Area of Science:

• Gastroenterology and Internal Medicine
• Immunology and Pharmacology

Background:

• Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel diseases (IBD) with diverse presentations and systemic complications.
• Current management strategies for mild-to-moderate IBD include sulfasalazine and 5-aminosalicylates.
• Corticosteroids are primary for moderate-to-severe IBD but have toxicities and are ineffective for maintenance.

Purpose of the Study:

• To review current therapeutic approaches for managing Crohn's disease and ulcerative colitis.
• To highlight the evolving landscape of IBD treatment, including immunomodulators and biologic therapies.
• To discuss the role of cyclosporine (CSA) as an alternative in severe cases.

Main Methods:

• Review of established and novel therapeutic agents for IBD.
• Discussion of treatment strategies based on disease severity and type (CD vs. UC).
• Consideration of long-term management, including maintenance therapy and toxicity profiles.

Main Results:

• Sulfasalazine and 5-aminosalicylates are effective for mild-to-moderate IBD.
• Immunomodulators (azathioprine, 6-MP) are increasingly used for steroid-dependent/resistant IBD due to corticosteroid limitations.
• Infliximab represents a new biologic therapy for active and fistulizing CD.
• Cyclosporine (CSA) is an alternative for severe UC unresponsive to corticosteroids and for severe/fistulizing CD.

Conclusions:

• Advances in understanding IBD pathogenesis are driving innovative therapeutic approaches.
• Current treatments can significantly reduce morbidity and improve the quality of life for IBD patients.
• Continued research is essential for developing eventual cures for these chronic conditions.